Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Albertsons Companies , Inc. (NYSE:ACI) stands as a prominent player in the U.S. grocery market, with annual revenue reaching $79.93 billion, leveraging its scale and diverse offerings to maintain a ...

Visa Inc . (NYSE:V), a global leader in digital payments, continues to demonstrate strong performance and resilience in the ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

“At the first prespecified interim analysis, Libtayo achieved a remarkably high bar in improving disease-free survival in high-risk cutaneous squamous cell carcinoma. With no currently approved ...

Additionally, the success of Libtayo in the treatment of cutaneous squamous cell carcinoma further supports the optimistic outlook. These factors collectively contribute to the positive assessment ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

EYLEA HD achieved $6 billion in 2024 sales, with FDA decisions on extended dosing and pre-filled syringes due in 2025. Dupixent sales topped $15 billion in 2024, with strong COPD launch and Phase ...

The pharma plans to continue the study’s follow-up—including an analysis of overall survival—building up to a regulatory submission planned for the first half of 2025. Libtayo is a fully human ...

According to InvestingPro analysis, Regeneron maintains strong financial health with robust cash flows and minimal debt exposure. The C-POST study involved 415 patients who were randomized to receive ...